Drugs / ACT001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05053880 | Sep 2021 → Oct 2024 overdue | glioblastoma | Accendatech USA Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06838676 | Jul 2025 → Jul 2028 expected | diffuse midline glioma, H3 K27-altered | Nationwide Children's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06894225 | Mar 2025 → May 2026 | glioblastoma | National Neuroscience Institute | Suspended | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT06594211 | Oct 2024 → Oct 2028 expected | plasma cell myeloma | RenJi Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06594211 ↗ |
| Route | Oral | “ACT001 by mouth” NCT05053880 ↗ |